Compare · KMTS vs WST
KMTS vs WST
Side-by-side comparison of Kestra Medical Technologies Ltd. (KMTS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KMTS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 15.5x KMTS ($1.58B).
- KMTS has been more active in the news (19 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 9 for KMTS).
- Company
- Kestra Medical Technologies Ltd.
- West Pharmaceutical Services Inc.
- Price
- $26.95+0.26%
- $348.50-1.36%
- Market cap
- $1.58B
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 19
- 1
- Recent ratings
- 9
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KMTS
- Officer Webster Brian Daniel sold $412,180 worth of shares (15,000 units at $27.48) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 460,215 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.
- Chief Financial Officer Mahboob Vaseem sold $680,383 worth of shares (26,287 units at $25.88) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 60,609 units (SEC Form 4)
- Analyst initiated coverage on Kestra Medical Technologies with a new price target
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- Chief Commercial Officer Ford Alfred J Jr sold $151,141 worth of shares (6,275 units at $24.09), decreasing direct ownership by 6% to 99,564 units (SEC Form 4) (tax liability)
- Chief Financial Officer Mahboob Vaseem sold $172,635 worth of shares (6,995 units at $24.68) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 86,896 units (SEC Form 4) (withholding tax)
- Officer Umberger Traci S sold $86,073 worth of shares (3,580 units at $24.04), decreasing direct ownership by 2% to 195,825 units (SEC Form 4) (tax withholding)
- Officer Webster Brian Daniel sold $1,272,588 worth of shares (51,900 units at $24.52), decreasing direct ownership by 10% to 475,215 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target